In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
摘要:
Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5 nM and good selectivity profiles against a number of related kinases including ERK, p38 alpha and JNKs. TNF alpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNF alpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
摘要:
Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5 nM and good selectivity profiles against a number of related kinases including ERK, p38 alpha and JNKs. TNF alpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNF alpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof:
wherein the groups R1, R2, R3, R7 and X are as defined in the specification.
化合物(I)的公式或其药学上可接受的盐或前药酯:其中,基团R1、R2、R3、R7和X如规范所定义。
[EN] PYRROLO ISOQUINOLINES AS KINASE INHIBITORS<br/>[FR] PYRROLO ISOQUINOLINES COMME INHIBITEURS DE KINASE
申请人:NOVARTIS AG
公开号:WO2008025512A1
公开(公告)日:2008-03-06
[EN] A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1, R2, R3, R7 and X are as defined in the specification. [FR] L'invention concerne un composé représenté par la formule (I) ou un sel acceptable du point de vue pharmaceutique ou un ester promédicament de celui-ci : où les groupes R1, R2, R3, R7 et X sont tels que définis dans la description.
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5 nM and good selectivity profiles against a number of related kinases including ERK, p38 alpha and JNKs. TNF alpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNF alpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.